Foghorn Therapeutics Inc.

NASDAQ:FHTX

9.56 (USD) • At close September 18, 2024
Bedrijfsnaam Foghorn Therapeutics Inc.
Symbool FHTX
Munteenheid USD
Prijs 9.56
Beurswaarde 528,942,372
Dividendpercentage 0%
52-weken bereik 2.7 - 10.25
Industrie Biotechnology
Sector Healthcare
CEO Mr. Adrian H. B. Gottschalk
Website https://foghorntx.com

An error occurred while fetching data.

Over Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic

Vergelijkbare Aandelen

Castle Biosciences, Inc. logo

Castle Biosciences, Inc.

CSTL

30.36 USD

Sangamo Therapeutics, Inc. logo

Sangamo Therapeutics, Inc.

SGMO

0.837 USD

The Pennant Group, Inc. logo

The Pennant Group, Inc.

PNTG

34.99 USD

Bioventus Inc. logo

Bioventus Inc.

BVS

11.69 USD

Surmodics, Inc. logo

Surmodics, Inc.

SRDX

39.3 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)